About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Biomarker for Rare Autoimmune Disease Discovered

by Adeline Dorcas on August 30, 2019 at 2:48 PM
Font : A-A+

New Biomarker for Rare Autoimmune Disease Discovered

Newly discovered biomarker could pave the way for developing new, personalized treatments for myasthenia gravis (MG), a rare autoimmune disease that causes weakness in the skeletal muscles. The findings of the study are published in the journal Metabolomics.

University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.

Advertisement


In a study, neurologist Zaeem Siddiqi, graduate student Derrick Blackmore and their team used metabolic analysis of serum (blood with all cells removed) to find a unique pattern of metabolites--products of the body's metabolic processes such as amino acids, vitamins or antioxidants--that is specific to myasthenia gravis.

Siddiqi and his team first compared the serum of patients with myasthenia gravis to a healthy control group. They then performed a comparison of serum from myasthenia patients to serum from rheumatoid arthritis, another autoimmune disease. After identifying more than 10,000 compounds in the serum samples, they found a unique pattern of 12 metabolites exclusive to patients with myasthenia gravis.
Advertisement

"This is really important because now we have a way to easily separate a patient with myasthenia gravis from someone with rheumatoid arthritis or another autoimmune disease," said Siddiqi, a member of the U of A's Women's and Children's Health Research Institute and the Neuroscience and Mental Health Institute.

"What's more, now we're able to explore how those 12 metabolites change in mild, moderate or severe cases so we can make this biomarker more robust and more effective for predicting the course of the disease and developing treatment plans."

The rare autoimmune disease affects approximately one in 5,000 people, most often women under age 40 or men over 60. Typically, the disease affects the voluntary muscles in the face, head and neck and may affect torso and limb muscles as well. Patients can experience eyelid drooping and double vision, difficulty speaking and chewing, and weakness in the limbs. In severe cases, the disease can affect breathing and swallowing muscles, which can be fatal.

The results highlight the potential metabolomic profiling has in identifying disease biomarkers.

"Right now we don't have the ability to manage myasthenia gravis in a more specific way; we treat all patients the same," said Siddiqi.

"Now we have a unique fingerprint or map of metabolites that can easily separate healthy individuals from those with myasthenia gravis, and a path to the discovery of more accurate and specific treatments."

Biomarkers are useful in managing diseases because they not only help in early diagnosis of a disease, but can also help outline its severity, predict the course and expected outcomes, and indicate what treatments would be the most effective.

"Biomarker discovery is an important step in individualized medicine," said Siddiqi.

According to Siddiqi, current methods for diagnosing myasthenia gravis only tell physicians whether or not a patient has the disease. There are no other biomarkers that can reliably predict the course of myasthenia gravis in a patient, or the best therapeutic response. Although there is no known cure, there are treatments for the disease that can manage the symptoms throughout the rest of the patient's life. Even so, because myasthenia gravis is so rare, treatments can be extremely expensive, hard to find and not tailored to the patient, Siddiqi said.

"Finding the antibodies is good for diagnosis, but they do not tell us how the patient will react to a specific drug or which drug will be most effective," Siddiqi said. "What we're trying to do with this biomarker discovery is develop treatments specific to the needs of the patient, to have more precise management and to be able to more accurately predict the effects of the treatments."

Siddiqi is hoping to soon expand the team's research by examining patients at different stages of the disease to get a more precise picture of how each stage affects the metabolites, and make their biomarker more robust.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Systemic Lupus Erythematosus Chemotherapy Chemotherapy Drugs Multiple Sclerosis Myasthenia Gravis Multiple Sclerosis Treatment and Modify Vitiligo Autoimmune Disorders Granulomatosis with Polyangiitis (GPA) Microscopic Polyangiitis 

Recommended Reading
Myasthenia Gravis
Myasthenia gravis is the commonest disorder of neuromuscular transmission. Autoimmune myasthenia ......
New Light Shed On Muscle-weakening Disease Myasthenia Gravis By Researchers
Researchers report that an antibody to a protein critical to enabling the brain to talk to muscles ....
Autoimmune Disease Myasthenia Gravis Halted in Mice By Researchers
A gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis was ....
Therapy for Autoimmune Disorder of Muscle Weakness
Myasthenia gravis is a non-inherited autoimmune form of muscle weakness and nearly 60,000 American ....
Autoimmune Disorders
Autoimmune disorders occur when the immune system fails to recognize the body as ‘self’ and attacks ...
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body....
Granulomatosis with Polyangiitis (GPA)
Granulomatosis with Polyangiitis (GPA) is a type of vasculitis that usually affects the upper airway...
Microscopic Polyangiitis
Microscopic polyangitis, infection of small blood vessels, presents with general symptoms of fever, ...
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulat...
Multiple Sclerosis Treatment and Modify
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity an...
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organs like the jo...
Vitiligo
Vitiligo is a skin disease characterized by patches of unpigmented skin. Vitiligo is usually slowly ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)